82 search results found

  • figur8, Inc.

    Boston, MA
    Consumer Products
    FIGUR8 has developed the first musculoskeletal diagnostics decision support system of its kind that can accurately pinpoint the source and severity of an injury while showing real-time recovery visibility. FIGUR8 began as a collaboration between MIT Media Lab researchers, Massachusetts General... More
    Keywords:
    MSK, musculoskeletal health, digital physical exam, digital health, Medical Device, MSK data, AI diagnostic, injury evaluation, injury recovery
  • Tue, July 16, 2024 | Conference

    2024 MIT Tokyo Life Science Symposium - Startup Exchange Lightning Talks

    Tokyo, Japan

    Startup Lightning Talks presented at the 2024 MIT Tokyo Life Science Symposium.

     

     

  • AI Driven Bloodless Blood Tests: GPx

    January 24, 2025 | Startup Exchange Video | Duration: 7:47

    AI Driven Bloodless Blood Tests
    Sean (Shunsuke) Matsuoka, Co-Founder & COO, GPx
    GPx: https://gpx.ai/

    In an aging society, the number of heart failure patients is increasing, making the prevention of readmissions and reduction of medical costs critical issues. Remote monitoring using invasive implantable devices has proven effective in reducing heart failure readmissions, but its use remains limited.

    To address this, GPx has developed an algorithm that non-invasively predicts signs of heart failure exacerbation. This algorithm was created using clinical trial data from monitoring 245 heart failure patients over 6 months to a year at eight facilities, including the Mayo Clinic in the U.S. The algorithm links digital 
    biomarker data with vital blood tests (NT-proBNP and creatinine) to achieve high-precision prediction and early medical intervention.

    Additionally, with a grant of 1.2 billion yen provided through AMED, we are collaborating with the National Cerebral and Cardiovascular Center (Dr. Chisato Izumi) to conduct a clinical trial involving 400 patients starting April 2025. The trial will be conducted at the National Cerebral and Cardiovascular Center, Kyoto University, Kobe University, and Kochi University.

    Furthermore, at this year's MIT Japan Conference, we will unveil a groundbreaking point-of-care (POC) potassium testing device for the first time. At the conference, we aim to explore the feasibility of applying our technology to other conditions (such as kidney failure, pulmonary arterial hypertension, and cardio-oncology) and to assess the potential for providing algorithm-based services for heart failure patients within Japan.

  • Past Deadline: Oct 6, 2019

    Leading petrochemical company seeks startups in Data Management for Oct 8-10

    meeting

    Senior executives from TOTAL will be visiting MIT from Oct 8-10 for the purpose of exploring potential partnerships with MIT startups. The goal of October’s visit is to meet experts that can help to find the best way to enhance Data Management (DM) practices throughout TOTAL entities. Data must be managed effectively and valued to maximize its business impact. Attendees from TOTAL include Michel Lutz, Group Data Officer, and Gaile Lejay, Business analyst.

  • DeepCure Inc.

    Boston, MA
    Biotechnology
    DeepCure develops disruptive Artificial Intelligence technology to revolutionize pharmaceutical development. The pharma industry is undoubtedly one of the world's largest, with worldwide revenues topping one trillion US dollars. However, its effectiveness is in question, as the exponentially... More
    Keywords:
    Artificial Intelligence, Deep Learning, Drug discovery, drug development, Biotechnology, Generative Drug Design, AI Driven Lead Optimization, Lead Discovery, Computational Chemistry, Beyond State-of-Art Machine Learning

  • Cracking Cancer 2.0 - Panel Discussion

    December 7, 2017 | Startup Exchange Video | Duration: 47:30

    Trond Undheim, PhD, Program Director, MIT Startup Exchange; Paula Hammond, PhD, David H. Koch Professor in Engineering and Department Head, Chemical Engineering, MIT; Laura Indolfi, PhD, CEO of PanTher Therapeutics; Peter Sandor, VP, Head of Oncology Marketing Strategy, Astellas.

  • Past Deadline: Jun 21, 2021

    P&G Seeks Startups for 2 Innovation Briefs

    partnership

    P&G is looking for new approaches and technologies that can help them to address key business challenges/opportunities.

  • AdaViv

    Somerville, MA
    Agriculture
    AdaViv is aiming to fundamentally change the way we grow crops in controlled-environments with the aid of sensing and computing technologies. We provide farmers with valuable insights on the health of their growing plants by capturing new types of high-throughput sensing data and using... More

  • PathAI

    November 15, 2018 | Startup Exchange Video | Duration: 21:45

    PathAI is evolving pathology using machine learning and deep learning techniques to drive faster more accurate diagnosis of disease.

  • Synthetic Biology Workshop 2017 - Market Keynote - Trends in Synthetic Biology Investments

    September 12, 2017 | Startup Exchange Video | Duration: 13:35

    JC Gutiérrez-Ramos, President and CEO, Synlogic